Neuromodulation for ADHD
- Review of ADHD
- To understand the condition
- To explore the current pharmacologic and psychotherapeutic approaches
- Neuromodulation for ADHD: in the pipeline and FDA-cleared
- Q & A
Date of Release: Friday, January 7, 2022
Date of Expiration: January 6, 2024
Cost: Members: $25 | Non-members $50 | Student Members FREE
Ian Cook, MD, DFAPA
Dr. Cook is a Director of the Los Angeles TMS Institute, Inc., and Professor Emeritus of Psychiatry and Biobehavioral Sciences in UCLA’s David Geffen School of Medicine, where he previously held the Miller Family Endowed Chair in Depression Research, was Director of the UCLA Depression Research & Clinic Program, and was the Founding Director of the UCLA TMS Service. Dr. Cook earned his bachelors degree with high honors from Princeton University and his medical degree from the Yale University School of Medicine. He completed his psychiatry residency training at UCLA's Neuropsychiatric Institute, where he also was an NIMH-funded research fellow, before joining the faculty. Dr. Cook served on the Executive Committee on Practice Guidelines of the American Psychiatric Association and guided the electronic dissemination of their evidence-based guidelines in psychiatry. A board-certified Psychiatrist, he has also served as an examiner for the American Board of Psychiatry and Neurology. His biography is profiled in Who's Who in America, Who's Who in the World, and Best Doctors. He is the author of numerous publications on brain function in mental illness and in aging and holds several dozen patents on biomedical devices and methods.
Acknowledgement of Financial and/in In-Kind Commercial Support
No financial or in-kind commercial support was received for this educational activity.
Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. You must take in the entire activity as partial credit is not available.
If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Clinical TMS Society. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians (ACCME) Credit Designation
Amedco LLC designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Objectives - After Attending This Program You Should Be Able To
1. Discuss the condition of ADHD abd explore the current pharmacologic and psychotherapeutic.
2. Discuss neuromodulation for ADHD: in the pipeline and FDA-cleared tDCS, TMS, eTNS.
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-‐6.2, 6.5)
All individuals in a position to control the content of CE are listed below.
Ian Cook - NeoSync, Inc.:Research Grant Site Principal Investigator, NeuroSigma, Inc.:Stock Shareholder, HeartCloud, Inc.:Employee, HeartCloud, Inc.:Corporate Board Member, HeartCloud, Inc.:Stock Shareholder, BrainCloud Corporation:Employee, BrainCloud Corporation:Corporate Board Member, BrainCloud Corporation:Stock Shareholder, Clinical Cloudworks, Inc.:Other, UCLA TDG:Patent Holder
Sheryl Morgan - Nothing to disclose
Ashleigh Servadio - Nothing to disclose
Questions? Email Certificate@AmedcoEmail.com